The odds of treatment failure among patients on ADA versus INF stayed significant (OR = 26.91, 95% CI [7.75–93.39], p = 0.0001), even after controlling for age, gender, type of IBD (UC vs. CD), disease location for UC patients and behavior for CD patients, and duration of illness, as shown in Table 3. The gene discussed is CBLIF; the disease is inflammatory bowel disease.